Malaysian Journal of Oncology Research

27/04/2023

Tumor drug in a hydrogel to stimulate tumor-associated macrophages for postoperative treatment of glioblastoma

Medication delivered by a novel gel cured 100% of mice with an aggressive brain cancer, a striking result that offers new hope for patients diagnosed with glioblastoma, one of the deadliest and most common brain tumors in humans.

The team combined an anticancer drug­­­ and an antibody in a solution that self-assembles into a gel to fill the tiny grooves left after a brain tumor is surgically removed. The gel can reach areas that surgery might miss and current drugs struggle to reach to kill lingering cancer cells and suppress tumor growth.

http://sciencemission.com/site/index.php?page=news&type=view&id=cancer%2Ftumor-drug-in-a&filter=8%2C9%2C10%2C11%2C12%2C13%2C14%2C16%2C17%2C18%2C19%2C20%2C27

26/04/2023

Please share to those whom may concerned.

01/07/2018

ESPOD Fellowship at the EMBL-EBI & Wellcome Trust Sanger Institute, Hinxton, near Cambridge, UK Project: Context dependent changes of signalling

03/12/2017

➖➖➖➖➖➖➖➖➖➖➖➖
New Drugs: 2017 till November
➖➖➖➖➖➖➖➖➖➖➖➖

1. Avelumab: Anti PD1 (Programmed Death ligand 1 Ab approved for metastatic Merkel cell carcinoma.

2. Dupilumab: Anti IL 4 receptor alpha antibody approved for treatment of atopic dermatitis.

3. Brodalumab: Anti IL 17 A receptor Ab approved for treatment of plaque psoriasis.

4. Plecanatide: Guanylate c*clase c stimulator approved for treatment of chronic idiopathic constipation. It increases c*c GMP, which stimulates CTFR ( Cystic Fibrosis Transmembrane Regulator), which increases Cl ion secretion in to gut.

5. Naldenedine: Opioid antagonist approved for treatment of opioid induced constipation.

6. Telotristat: Tryptophan hydroxylase inibitor approved for treatment of carcinoid syndrome. It inhibits serotonin synthesis.

7. Midostaurin: Multikinase inhibitor approved for treatment of
• AML: Along with TOC (Cytarabine + Daunorobicin) in FLT3 mutation positive cases.
• Aggressive systemic mastocytosis
• Systemic mastocytosis with hematological neoplasm
• Mast cell leukemia

8. Ocrelizumab: Anti CD20 Ab approved for treatment of RRMS and PPMS.

9. Deflazacort: Corticosteroid approved for treatment of Duchenne muscular dystrophy.

10. Abolaparatide: PTH anaog approved for treatment of resistant postmenopausal osteoporosis at high risk of fracture.

11. Deutetrabenazine: VMAT 2 inhibitor approved for treatment of Hutington's chorea.

12. Valbenazine: VMAT 2 inhibitor approved for treatment of tardive dyskinesia.

13. Safinamide: MAO B inhibitor approved for treatment of on off phenomena seen with levodopa.

14. Rivociclib: CDK (Cyclin Dependent Kinase) 4 and 6 inhibitor approved for treatment of ER +ve post menopausal breast cancer along with aromatase inhibitors.

15. Niraparib: Poly ADP-Ribose Polymerase (PARP) inhibitor approved for treatment of ovarian, fallipian tube and primary peritoneal cancer resistant to cisplatin.

16. Brigatinib: Multikinase inhibitor approved for treatment of advanced ALK-positive metastatic non-small cell lung cancer.

17. Betrixaban - Oral factor Xa inhibitor approved for pophylaxis of venous thromboembolism.

18. Delafloxacin - A new fluoroquinolone approved for treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by both gram positive and negative organisms.

19. Guselkumab - Anti IL 23 MAb approved for treatment of plaque psoriasis.

20. Dapagliflozin + Saxagliptin: FDC approved for treatment of type II DM.

21. Inotuzumab ozogamycin: Anti CD 22 MAb approved for treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

22. Enasidenib: It is an inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme that works by blocking several enzymes that promote cell growth. It is approved for treatment of relapsed or refractory acute myeloid leukemia with IDH2 mutation.

23. Glecaprevir (Hep C protease inhibitor) and Pibrentasvir (Hep C NS5A inhibitor): FDC approved for treatment of hepatitis C.

24. Meropenam + Vaborbactam - Approved for treatment of complicated UTI.

25. Lesinurad (Uricosuric) + Allopurinol: FDC approved for gout in case of allopurinol ineffectiveness.

26. Sarilumab: Anti IL6 MAb approved for treatment of rheumatoid arthritis.

27. Edaravone: It is a free radical scavenger approved for treatment of ALS.

28. Amantidine: Approved for treatment of dyskinesia in PD.

29. Neratinib: Inhibitor of EGFR, HER-2
and Her-4 tyrosine kinase approved for treatment of trastuzumab resistant breast cancer.

30. Copanlisib: Inhibitor of PI3 kinase-alpha and PI3 kinase-delta approved for treatment of relapsed follicular lymphoma in adults with at least prior two systemic therapies.

31. Acalabrutinib: Brutons tyrosine kinase inhibitor approved for treatment of mantle cell lymphoma in patients who have received a least prior one therapy.

32. Emicizumab-kxwh: Bispecific anti factor IXa and factor X antibody approved to prevent bleeding in patients with hemophilia A .

33. Secnidazole: Nitroimidazole antimicrobial approved for treatment of bacterial vaginosis.

34. Abemaciclib: Cyclin dependent kinase 4 and 6 inhibitor approved for treatment of ER/PR positive advanced or metastatic breast cancer as monotherspy or along with fluvestrant.

22/08/2017

Infectious mononucleosis is the clinical syndrome associated with acute EBV infection. EBV infection typically occurs during one of two distinct time periods; the first wave of infection occurs during early childhood, before the age of 5 years, and the second wave occurs during the second and third decades of life. Most adults have been infected with EBV, and only 3 to 10% of adults older than 40 years of age have not been infected. As compared with children and young adults, older patients with primary EBV infection are less likely to present with pharyngitis and are more likely to have severe illness that necessitates hospitalization. Primary EBV infection is characterized by abnormal results on flow cytometry of the peripheral blood, including an inverted CD4:CD8 ratio and frequent down-regulation of certain pan–T-cell antigens. The presence of an expanded CD8+ T-cell population corresponds to the presence of atypical-appearing lymphocytes on peripheral-blood smears. Biopsy specimens of affected lymph nodes and tonsils show a number of morphologic features that mimic the features of lymphoma, including architectural distortion, an immunoblastic proliferation with cytologic atypia, and necrosis.

09/08/2017

http://sciencemission.com/data/attachment.php?id=4721 ()

26/06/2017

26/04/2017

http://sciencemission.com/data/attachment.php?id=4425 ()

29/03/2017

Zejula is designed to block an enzyme involved in repairing damaged DNA. The thought is that by blocking this enzyme, cancer cells would die and slow down or stop tumor growth, the FDA said.